Search Results: PTAB + IPR

Big Molecule Team at 2016 BIO IPCC Fall Conference

If you plan to attend next week’s 2016 BIO Intellectual Property Counsels Committee Fall Conference, please keep an eye out for members of the Big Molecule Watch team.  Big Molecule Watch editor Cynthia Hardman will moderate the conversation during the day-two luncheon fireside chat, “Standing on the Front Lines: Trials…

Read More

PTO Publishes New PTAB Rules

On April 1, the U.S. Patent & Trademark Office published new rules for AIA proceedings before the Patent Trial & Appeal Board, including inter partes reviews (IPRs).  IPRs are becoming an important tool for biosimilar manufacturers to challenge patents on biologic drugs (for example, see here, here, and here). Some of the most…

Read More

Biologics, Biosimilars, and the Biologics Price Competition and Innovation Act (“BPCIA”): A Short Primer

Below we provide a short introduction to the world of biologics and the BPCIA. For a more comprehensive guide on biosimilars, check out Goodwin Procter’s Biosimilars: A Guide to Regulatory and Intellectual Property Issues. What are biologics? Biologics are medical products such as vaccines, therapeutic proteins, and gene therapies that…

Read More